Kortekaas-Rijlaarsdam, Anne Fleur
Luman, Marjolein
Sonuga-Barke, Edmund
Oosterlaan, Jaap
Funding for this research was provided by:
Shire
Article History
Received: 13 June 2017
Accepted: 4 January 2018
First Online: 20 January 2018
Compliance with ethical standards
:
: Anne Fleur Kortekaas-Rijlaarsdam MSc., Dr. Marjolein Luman has no conflicts of interest to declare. Prof. Dr. Jaap Oosterlaan (last 3 years): research funding (investigator initiated trial) from Shire Pharma. Prof. Dr. Edmund Sonuga-Barke (last 3 years): speaker fees, consultancy and conference support from Shire Pharma. Speaker fees from Janssen Cilag, consultancy from Neurotech solutions, Aarhus University, Copenhagen University and Berhanderling, Skolerne, Copenhagen, KU Leuven. Book royalties from OUP and Jessica Kingsley.